好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluation of Psychiatric History and Symptom Discordance in Neuro-PASC Patients: A Cross-Sectional Study
Infectious Disease
P8 - Poster Session 8 (8:00 AM-9:00 AM)
10-007

Compare self-reported psychiatric symptoms in Neuro-PASC patients to standardized tools.

Studies regarding COVID-19 have been ongoing, as patients continue to present with various cognitive-psychiatric symptoms for more than 12 weeks post-infection—a condition known as Neuro-PASC. While literature points out to past psychiatry history as a risk factor to long covid development, there were gaps in literature regarding evaluating the clinical accuracy in self-reported symptoms. Hence, this left an unanswered question whether long COVID is over or under diagnosed based solely on self-reported symptoms.

Through a cross-sectional design, controls and patients underwent various health questionnaires, notably the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7), to scale depression and anxiety intensity. Anxiety and depression were specifically questioned when taking participants health and long COVID symptoms history.

The patient group (n=26) had a prevalence of 38% for a history of depression and 35% for a history of anxiety, while controls group (n=15) had 20% and 7%, respectively. There was a statistically significant increase in PHQ-9 and GAD-7 scores in patients who had a pre-COVID history of depression or anxiety. Qualitative analyses showed a large proportion of patients with no self-reported depression had moderate-severe depression scores. Similarly, in the case of anxiety, it was noted that 40% of patients with severe anxiety scores had not reported this finding, and a bit less than 20% of patients who reported anxiety had none according to the GAD-7 scale.

This study supports the literature findings that pre-covid psychiatric history is a risk factor for long COVID development and severity. This study also highlights the discordance between self-reported symptoms and validated scales. It would be interesting to explore further whether the presence of current psychiatric symptoms in patients is secondary to COVID-19, requiring a pathological trigger to surge, or were rather omnipresent before the infection.

Authors/Disclosures
Lina Al Qadi
PRESENTER
Miss Al Qadi has nothing to disclose.
Josiane Stadler Ms. Stadler has nothing to disclose.
Dominique Comeau (Vitalité Health Network) Dominique Comeau has nothing to disclose.
Véronique Landry, MD Dr. Landry has received personal compensation in the range of $50,000-$99,999 for serving as a Trainee in the Royal College of Physicians and Surgeons of Canada : Clinicial-Investigator Program with Vitalité Health Network.
Mahée Cote, Medical Student Miss Cote has nothing to disclose.
Marie-Claire Losier, DPs, LPsych Dr. Losier has nothing to disclose.
Emilie Laplante, PsyD Dr. Laplante has nothing to disclose.
Gilles A. Robichaud, PhD Prof. Robichaud has stock in Agrogene solutions Inc . The institution of Prof. Robichaud has received research support from Canadian cancer society .
Luc Boudreau, PhD Dr. Boudreau has nothing to disclose.
Robert Laforce, Jr., MD, PhD (CHU De Quebec) Dr. Laforce has nothing to disclose.
Ludivine Chamard Witkowski Ludivine Chamard Witkowski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Ludivine Chamard Witkowski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for merck Serono. The institution of Ludivine Chamard Witkowski has received research support from CFMNB. The institution of Ludivine Chamard Witkowski has received research support from Cantrain.